Early screening and genomic profiling reshape lung cancer care
Lung cancer is the leading cause of cancer deaths, with NSCLC making up 80–85% of cases. Annual low-dose CT screening is recommended for adults 50–80 with a 20-pack-year history to detect cancer early. Comprehensive genomic profiling (biomarker testing) identifies actionable targets in many NSCLC cases, guiding personalized treatment and helping choose the best options—often after CGP results are available. Patients and families should advocate for CGP and awareness of screening, as early detection and precision medicine drive better outcomes.
